# Supernus Pharmaceuticals, Inc.: financial statements, quarterly

SUPN · Nasdaq · CIK 1356576 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/supn.md) · [Financials](/companies/supn/financials.md) · [Filings](/companies/supn/filings.md) · [Insiders](/companies/supn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/supn/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [164 d](/filings/0001356576-26-000011.md) | [144](/filings/0001356576-25-000033.md) | [168](/filings/0001356576-25-000055.md) | [176](/filings/0001356576-25-000071.md) | [174 d](/filings/0001356576-26-000011.md) | [150](/filings/0001356576-26-000022.md) | [165](/filings/0001356576-26-000037.md) | [192](/filings/0001356576-26-000051.md) | [212 d](/filings/0001356576-26-000011.md) | [208](/filings/0001356576-26-000022.md) | [219](/filings/0001356576-26-000037.md) | [227](/filings/0001356576-26-000051.md) |
| Cost of revenue | $m | [19.6 d](/filings/0001356576-26-000011.md) | [16.3](/filings/0001356576-25-000033.md) | [17.9](/filings/0001356576-25-000055.md) | [17.6](/filings/0001356576-25-000071.md) | [26.1 d](/filings/0001356576-26-000011.md) | [15.8](/filings/0001356576-26-000022.md) | [16.8](/filings/0001356576-26-000037.md) | [19.0](/filings/0001356576-26-000051.md) | [23.0 d](/filings/0001356576-26-000011.md) | [23.4](/filings/0001356576-26-000022.md) | [33.7](/filings/0001356576-26-000037.md) | [27.0](/filings/0001356576-26-000051.md) |
| Research and development | $m | [23.3 d](/filings/0001356576-26-000011.md) | [24.9](/filings/0001356576-25-000033.md) | [26.2](/filings/0001356576-25-000055.md) | [29.0](/filings/0001356576-25-000071.md) | [28.6 d](/filings/0001356576-26-000011.md) | [26.9](/filings/0001356576-26-000022.md) | [22.1](/filings/0001356576-26-000037.md) | [29.4](/filings/0001356576-26-000051.md) | [27.8 d](/filings/0001356576-26-000011.md) | [39.4](/filings/0001356576-26-000022.md) | [29.5](/filings/0001356576-26-000037.md) | [25.8](/filings/0001356576-26-000051.md) |
| Selling, general and administrative | $m | [81.3 d](/filings/0001356576-26-000011.md) | [86.5](/filings/0001356576-25-000033.md) | [85.9](/filings/0001356576-25-000055.md) | [69.8](/filings/0001356576-25-000071.md) | [79.4 d](/filings/0001356576-26-000011.md) | [89.9](/filings/0001356576-26-000022.md) | [93.6](/filings/0001356576-26-000037.md) | [180](/filings/0001356576-26-000051.md) | [122 d](/filings/0001356576-26-000011.md) | [125](/filings/0001356576-26-000022.md) | [134](/filings/0001356576-26-000037.md) | [128](/filings/0001356576-26-000051.md) |
| Operating income | $m | [(1.0) d](/filings/0001356576-26-000011.md) | [(3.2)](/filings/0001356576-25-000033.md) | [22.6](/filings/0001356576-25-000055.md) | [40.8](/filings/0001356576-25-000071.md) | [21.4 d](/filings/0001356576-26-000011.md) | [(10.3)](/filings/0001356576-26-000022.md) | [12.1](/filings/0001356576-26-000037.md) | [(60.2)](/filings/0001356576-26-000051.md) | [(3.9) d](/filings/0001356576-26-000011.md) | [(8.3)](/filings/0001356576-26-000022.md) | [(58.0)](/filings/0001356576-26-000037.md) | [21.2](/filings/0001356576-26-000051.md) |
| Interest expense | $m | [0.0 d](/filings/0001356576-26-000011.md) | [0.0](/filings/0001356576-24-000028.md) | [0.0](/filings/0001356576-24-000051.md) | [0.0](/filings/0001356576-24-000067.md) | [0.0 d](/filings/0001356576-26-000011.md) | not reported | [0.0](/filings/0001356576-26-000037.md) | [0.0](/filings/0001356576-26-000051.md) | [0.0 d](/filings/0001356576-26-000011.md) | not reported | [2.3](/filings/0001356576-26-000037.md) | [0.7](/filings/0001356576-26-000051.md) |
| Income tax | $m | [(0.2) d](/filings/0001356576-26-000011.md) | [0.1](/filings/0001356576-25-000033.md) | [6.4](/filings/0001356576-25-000055.md) | [6.4](/filings/0001356576-25-000071.md) | [11.1 d](/filings/0001356576-26-000011.md) | [6.0](/filings/0001356576-26-000022.md) | [(5.8)](/filings/0001356576-26-000037.md) | [(12.8)](/filings/0001356576-26-000051.md) | [2.2 d](/filings/0001356576-26-000011.md) | [(3.7)](/filings/0001356576-26-000022.md) | [0.7](/filings/0001356576-26-000037.md) | [1.8](/filings/0001356576-26-000051.md) |
| Net income | $m | [1.2 d](/filings/0001356576-26-000011.md) | [0.1](/filings/0001356576-25-000071.md) | [19.9](/filings/0001356576-25-000071.md) | [38.5](/filings/0001356576-25-000071.md) | [15.3 d](/filings/0001356576-26-000011.md) | [(11.8)](/filings/0001356576-26-000051.md) | [22.5](/filings/0001356576-26-000051.md) | [(45.1)](/filings/0001356576-26-000051.md) | [(4.1) d](/filings/0001356576-26-000011.md) | [(2.3)](/filings/0001356576-26-000051.md) | [(58.4)](/filings/0001356576-26-000051.md) | [20.9](/filings/0001356576-26-000051.md) |
| Diluted EPS | $ per share | not reported | [0.00](/filings/0001356576-25-000033.md) | [0.36](/filings/0001356576-25-000055.md) | [0.69](/filings/0001356576-25-000071.md) | not reported | [(0.21)](/filings/0001356576-26-000022.md) | [0.40](/filings/0001356576-26-000037.md) | [(0.80)](/filings/0001356576-26-000051.md) | not reported | [(0.04)](/filings/0001356576-26-000022.md) | [(1.01)](/filings/0001356576-26-000037.md) | [0.35](/filings/0001356576-26-000051.md) |
| Basic EPS | $ per share | not reported | [0.00](/filings/0001356576-25-000033.md) | [0.36](/filings/0001356576-25-000055.md) | [0.70](/filings/0001356576-25-000071.md) | not reported | [(0.21)](/filings/0001356576-26-000022.md) | [0.40](/filings/0001356576-26-000037.md) | [(0.80)](/filings/0001356576-26-000051.md) | not reported | [(0.04)](/filings/0001356576-26-000022.md) | [(1.01)](/filings/0001356576-26-000037.md) | [0.36](/filings/0001356576-26-000051.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [75.1](/filings/0001356576-26-000011.md) | [63.4](/filings/0001356576-24-000028.md) | [52.1](/filings/0001356576-24-000051.md) | [31.7](/filings/0001356576-25-000071.md) | [69.3](/filings/0001356576-26-000011.md) | [116](/filings/0001356576-26-000022.md) | [145](/filings/0001356576-26-000037.md) | [151](/filings/0001356576-26-000051.md) | [128](/filings/0001356576-26-000051.md) | [185](/filings/0001356576-26-000022.md) | [180](/filings/0001356576-26-000037.md) | [176](/filings/0001356576-26-000051.md) |
| Current assets | $m | [493](/filings/0001356576-25-000017.md) | [544](/filings/0001356576-24-000028.md) | [591](/filings/0001356576-24-000051.md) | [640](/filings/0001356576-24-000067.md) | [686](/filings/0001356576-26-000011.md) | [688](/filings/0001356576-25-000033.md) | [739](/filings/0001356576-25-000055.md) | [594](/filings/0001356576-25-000071.md) | [644](/filings/0001356576-26-000051.md) | [732](/filings/0001356576-26-000022.md) | [723](/filings/0001356576-26-000037.md) | [711](/filings/0001356576-26-000051.md) |
| Total assets | $m | [1,278](/filings/0001356576-25-000017.md) | [1,304](/filings/0001356576-24-000028.md) | [1,316](/filings/0001356576-24-000051.md) | [1,343](/filings/0001356576-24-000067.md) | [1,368](/filings/0001356576-26-000011.md) | [1,347](/filings/0001356576-25-000033.md) | [1,382](/filings/0001356576-25-000055.md) | [1,420](/filings/0001356576-25-000071.md) | [1,453](/filings/0001356576-26-000051.md) | [1,501](/filings/0001356576-26-000022.md) | [1,428](/filings/0001356576-26-000037.md) | [1,398](/filings/0001356576-26-000051.md) |
| Current liabilities | $m | [290](/filings/0001356576-25-000017.md) | [315](/filings/0001356576-24-000028.md) | [309](/filings/0001356576-24-000051.md) | [292](/filings/0001356576-24-000067.md) | [292](/filings/0001356576-26-000011.md) | [282](/filings/0001356576-25-000033.md) | [286](/filings/0001356576-25-000055.md) | [331](/filings/0001356576-25-000071.md) | [338](/filings/0001356576-26-000051.md) | [374](/filings/0001356576-26-000022.md) | [347](/filings/0001356576-26-000037.md) | [285](/filings/0001356576-26-000051.md) |
| Total liabilities | $m | [356](/filings/0001356576-25-000017.md) | [375](/filings/0001356576-24-000028.md) | [358](/filings/0001356576-24-000051.md) | [336](/filings/0001356576-24-000067.md) | [332](/filings/0001356576-26-000011.md) | [317](/filings/0001356576-25-000033.md) | [319](/filings/0001356576-25-000055.md) | [370](/filings/0001356576-25-000071.md) | [391](/filings/0001356576-26-000051.md) | [424](/filings/0001356576-26-000022.md) | [397](/filings/0001356576-26-000037.md) | [335](/filings/0001356576-26-000051.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [922](/filings/0001356576-26-000011.md) | [929](/filings/0001356576-25-000071.md) | [957](/filings/0001356576-25-000071.md) | [1,007](/filings/0001356576-25-000071.md) | [1,036](/filings/0001356576-26-000051.md) | [1,031](/filings/0001356576-26-000051.md) | [1,064](/filings/0001356576-26-000051.md) | [1,050](/filings/0001356576-26-000051.md) | [1,062](/filings/0001356576-26-000051.md) | [1,077](/filings/0001356576-26-000051.md) | [1,031](/filings/0001356576-26-000051.md) | [1,062](/filings/0001356576-26-000051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [45.0 d](/filings/0001356576-26-000011.md) | [38.4](/filings/0001356576-25-000033.md) | [35.6 d](/filings/0001356576-25-000055.md) | [53.5 d](/filings/0001356576-25-000071.md) | [44.4 d](/filings/0001356576-26-000011.md) | [30.6](/filings/0001356576-26-000022.md) | [58.5 d](/filings/0001356576-26-000037.md) | [(61.7) d](/filings/0001356576-26-000051.md) | [19.9 d](/filings/0001356576-26-000011.md) | [66.5](/filings/0001356576-26-000022.md) | [(4.8) d](/filings/0001356576-26-000037.md) | [6.6 d](/filings/0001356576-26-000051.md) |
| Capital expenditure | $m | [(0.0) d](/filings/0001356576-26-000011.md) | [0.2](/filings/0001356576-25-000033.md) | [0.1 d](/filings/0001356576-25-000055.md) | [0.2 d](/filings/0001356576-25-000071.md) | [0.2 d](/filings/0001356576-26-000011.md) | [0.3](/filings/0001356576-26-000022.md) | [0.5 d](/filings/0001356576-26-000037.md) | [0.1 d](/filings/0001356576-26-000051.md) | [0.4 d](/filings/0001356576-26-000011.md) | [0.0](/filings/0001356576-26-000022.md) | [0.6 d](/filings/0001356576-26-000037.md) | [0.2 d](/filings/0001356576-26-000051.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [62.5](/filings/0001356576-24-000028.md) | [54.5](/filings/0001356576-24-000051.md) | [54.6](/filings/0001356576-24-000067.md) | [55.6](/filings/0001356576-25-000033.md) | [55.7](/filings/0001356576-25-000055.md) | [56.0](/filings/0001356576-25-000071.md) | [55.9](/filings/0001356576-26-000022.md) | [56.6](/filings/0001356576-26-000037.md) | [56.6](/filings/0001356576-26-000051.md) | [57.6](/filings/0001356576-26-000022.md) | [58.1](/filings/0001356576-26-000037.md) | [59.5](/filings/0001356576-26-000051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 58,235,716 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0001356576-26-000051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 17:38 ET. No prices; not investment advice.